$TALK
Talkspace, Inc.

2024 Q2 Form 10-Q Financial Statement

#000095017024056301 Filed on May 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $46.06M $45.42M
YoY Change 29.21% 36.24%
Cost Of Revenue $25.11M $23.69M
YoY Change 40.79% 42.78%
Gross Profit $20.95M $21.73M
YoY Change 17.62% 29.75%
Gross Profit Margin 45.49% 47.85%
Selling, General & Admin $20.61M $18.21M
YoY Change 12.19% -3.32%
% of Gross Profit 98.39% 83.78%
Research & Development $2.163M $3.739M
YoY Change -48.14% -30.15%
% of Gross Profit 10.32% 17.21%
Depreciation & Amortization $220.0K $201.0K
YoY Change -27.15% -34.31%
% of Gross Profit 1.05% 0.92%
Operating Expenses $24.44M $23.41M
YoY Change 0.9% -9.22%
Operating Profit -$3.486M $1.679M
YoY Change -154.4% -81.42%
Interest Expense $3.044M $378.0K
YoY Change 77.8% -10.85%
% of Operating Profit 22.51%
Other Income/Expense, Net
YoY Change
Pretax Income -$442.0K $1.301M
YoY Change -109.41% -84.9%
Income Tax $32.00K $165.0K
% Of Pretax Income 12.68%
Net Earnings -$474.0K -$1.466M
YoY Change -89.92% -83.26%
Net Earnings / Revenue -1.03% -3.23%
Basic Earnings Per Share $0.00 -$0.01
Diluted Earnings Per Share $0.00 -$0.01
COMMON SHARES
Basic Shares Outstanding 169.7M 168.9M
Diluted Shares Outstanding 169.1M 168.8M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $114.9M $120.3M
YoY Change -8.87% -3.84%
Cash & Equivalents $114.9M $120.3M
Short-Term Investments
Other Short-Term Assets $2.302M $4.417M
YoY Change -21.16% 15.84%
Inventory
Prepaid Expenses
Receivables $11.55M $11.04M
Other Receivables $0.00 $0.00
Total Short-Term Assets $128.8M $135.7M
YoY Change -6.31% -3.98%
LONG-TERM ASSETS
Property, Plant & Equipment $2.544M
YoY Change 457.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.021M $2.546M
YoY Change 982.11% 391.51%
Total Long-Term Assets $5.021M $2.546M
YoY Change 63.18% -25.64%
TOTAL ASSETS
Total Short-Term Assets $128.8M $135.7M
Total Long-Term Assets $5.021M $2.546M
Total Assets $133.8M $138.3M
YoY Change -4.79% -4.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.733M $5.805M
YoY Change 41.01% -24.35%
Accrued Expenses $5.664M $4.647M
YoY Change -45.77% -10.22%
Deferred Revenue $2.733M $2.883M
YoY Change -25.79% -30.08%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.78M $15.69M
YoY Change -9.34% -27.37%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $635.0K $24.00K
YoY Change 115.25% -94.26%
Total Long-Term Liabilities $635.0K $24.00K
YoY Change 115.25% -94.26%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.78M $15.69M
Total Long-Term Liabilities $635.0K $24.00K
Total Liabilities $19.75M $18.70M
YoY Change -4.73% -19.21%
SHAREHOLDERS EQUITY
Retained Earnings -$272.3M -$271.9M
YoY Change 2.89% 4.57%
Common Stock $16.00K $16.00K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $114.0M $119.6M
YoY Change
Total Liabilities & Shareholders Equity $133.8M $138.3M
YoY Change -4.79% -4.49%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$474.0K -$1.466M
YoY Change -89.92% -83.26%
Depreciation, Depletion And Amortization $220.0K $201.0K
YoY Change -27.15% -34.31%
Cash From Operating Activities $4.809M -$3.391M
YoY Change 1564.01% -75.84%
INVESTING ACTIVITIES
Capital Expenditures $1.765M $385.0K
YoY Change 176400.0% 4177.78%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$1.765M -$385.0K
YoY Change 176400.0% -2126.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -8.409M 146.0K
YoY Change -1247.2% -73.74%
NET CHANGE
Cash From Operating Activities 4.809M -3.391M
Cash From Investing Activities -1.765M -385.0K
Cash From Financing Activities -8.409M 146.0K
Net Change In Cash -5.365M -3.630M
YoY Change -625.47% -73.04%
FREE CASH FLOW
Cash From Operating Activities $4.809M -$3.391M
Capital Expenditures $1.765M $385.0K
Free Cash Flow $3.044M -$3.776M
YoY Change 956.94% -73.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001803901
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
TALKSPACE, INC.
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-39314
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-4636604
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
622 Third Avenue
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10017
CY2024Q1 dei City Area Code
CityAreaCode
212
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
284-7206
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
169684974
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
120278000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
123908000
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
11035000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10174000
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
4417000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
5718000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
135730000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
139800000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2546000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2421000
CY2024Q1 us-gaap Assets
Assets
138276000
CY2023Q4 us-gaap Assets
Assets
142221000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5805000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6111000
CY2024Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2883000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3069000
CY2024Q1 talk Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
6998000
CY2023Q4 talk Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
12468000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
15686000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21648000
CY2024Q1 talk Warrant Liabilities Non Current
WarrantLiabilitiesNonCurrent
2988000
CY2023Q4 talk Warrant Liabilities Non Current
WarrantLiabilitiesNonCurrent
1842000
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
24000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
85000
CY2024Q1 us-gaap Liabilities
Liabilities
18698000
CY2023Q4 us-gaap Liabilities
Liabilities
23575000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
169569075
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
169569075
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
168428856
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
168428856
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
16000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
16000
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
391412000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
389014000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-271850000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-270384000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
119578000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
118646000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
138276000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
142221000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
45416000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33336000
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
23685000
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
16588000
CY2024Q1 us-gaap Gross Profit
GrossProfit
21731000
CY2023Q1 us-gaap Gross Profit
GrossProfit
16748000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3739000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5353000
CY2024Q1 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
1464000
CY2023Q1 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
1601000
CY2024Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
13009000
CY2023Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
13469000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5198000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5364000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
23410000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
25787000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
1679000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
9039000
CY2024Q1 talk Interest And Debt Expense Income
InterestAndDebtExpenseIncome
-378000
CY2023Q1 talk Interest And Debt Expense Income
InterestAndDebtExpenseIncome
-424000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1301000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
8615000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
165000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
143000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1466000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-8758000
CY2024Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.01
CY2024Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.01
CY2023Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.05
CY2023Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.05
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
168846946
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
168846946
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
161797781
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
161797781
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
118646000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
741000
CY2024Q1 talk Restricted Stock Units Vested
RestrictedStockUnitsVested
-595000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2252000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1466000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
119578000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
127536000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
621000
CY2023Q1 talk Restricted Stock Units Vested
RestrictedStockUnitsVested
-65000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2303000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-8758000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
121637000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1466000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-8758000
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
201000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
306000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2252000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2303000
CY2024Q1 talk Remeasurement Of Warrant Liabilities
RemeasurementOfWarrantLiabilities
-1146000
CY2023Q1 talk Remeasurement Of Warrant Liabilities
RemeasurementOfWarrantLiabilities
-189000
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
861000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2820000
CY2024Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-1301000
CY2023Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-559000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-306000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1213000
CY2024Q1 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
186000
CY2023Q1 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
232000
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-5470000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-6702000
CY2024Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-2000
CY2023Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-95000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3391000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14037000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
385000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9000
CY2024Q1 us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
0
CY2023Q1 us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
28000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-385000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
19000
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
741000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
621000
CY2024Q1 talk Payments For Employee Taxes Withheld Related To Restricted Stock Units Vested
PaymentsForEmployeeTaxesWithheldRelatedToRestrictedStockUnitsVested
595000
CY2023Q1 talk Payments For Employee Taxes Withheld Related To Restricted Stock Units Vested
PaymentsForEmployeeTaxesWithheldRelatedToRestrictedStockUnitsVested
65000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
146000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
556000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3630000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13462000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
123908000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
138545000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
120278000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
125083000
CY2024Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
15000
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
168000
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related notes to the condensed consolidated financial statements. The Company’s significant estimates and assumptions used in these condensed consolidated financial statements include, but are not limited to, the recognition and disclosure of revenue recognition, stock-based compensation awards and the fair value of warrant liabilities. The Company bases its estimates on historical factors, current circumstances and the experience and judgment of management. The Company evaluates its assumptions on an ongoing basis. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based on information available at the time they are made. Estimates, by their nature, are based on judgment and available information, therefore, actual results could be materially different from these estimates.</span></p>
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
45416000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33336000
CY2024Q1 us-gaap Legal Fees
LegalFees
0
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
168846946
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.5
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.5
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
0
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2252000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2303000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1466000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-8758000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
168846946
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
161797781
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
161797781
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2024Q1 talk Accrued Employee Compensation
AccruedEmployeeCompensation
2073000
CY2023Q4 talk Accrued Employee Compensation
AccruedEmployeeCompensation
7269000
CY2024Q1 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1831000
CY2023Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1525000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
743000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
626000
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2351000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3048000
CY2024Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6998000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
12468000
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
talk-20240331_htm.xml Edgar Link completed
0000950170-24-056301-index-headers.html Edgar Link pending
0000950170-24-056301-index.html Edgar Link pending
0000950170-24-056301.txt Edgar Link pending
0000950170-24-056301-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
talk-20240331.htm Edgar Link pending
talk-20240331.xsd Edgar Link pending
talk-ex31_1.htm Edgar Link pending
talk-ex31_2.htm Edgar Link pending
talk-ex32_1.htm Edgar Link pending
talk-ex32_2.htm Edgar Link pending